Improving Ventilatory Capacity in Those With Chronic High Level SCI

• Status: Recruiting
• Trial end date: 2022-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to find out if taking the drug Buspar will increase breathing capacity in individuals with spinal cord injuries.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Spaulding Rehabilitation Hospital
• Treatments: Buspirone

Criteria

Inclusion Criteria:

• Chronic high-level SCI (at least 24-months post injury)

• Age 18 to 50 years.

• Medically stable

• Spinal Cord Injury ≥T3

• American Spinal Injury Association grade A or B or C.

• Able to perform arm crank exercise.

Exclusion Criteria:

• Cardiomyopathy

• High blood pressure( >140/90 mmHg or you are taking high blood pressure medication)

• Significant irregular heartbeat

• Heart disease

• Chronic lung disease (COPD, bronchitis)

• Current use of cardioactive or antidepressant drugs

• Family history of significant irregular heart beat or sudden cardiac death

• Orthostatic hypotension (symptomatic fall in blood pressure >30 mmHg when upright)

• Current grade 2 or greater pressure ulcers at relevant contact site

• Neurological disease (stroke, peripheral neuropathy, myopathy)

• Arm or shoulder conditions that limit ability to perform arm crank exercise

• History of bleeding disorder, diabetes, kidney disease, cancer, other neurological disease

• Recent weigh change (greater than 10 pounds)

• Regular use of tobacco

• Intrathecal baclofen pump,

• Current use of cardioactive, antidepressant, other sedating agents

• Suicidal ideation

• Pregnant and/or breastfeeding women.

In addition, subjects must have no known hypersensitivity to Buspar and must not be taking a monoamine oxidase inhibitor.